Skip to main content

InMed Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

March 31,
2024June 30,
(unaudited)2023
$$
ASSETS
Current
Cash and cash equivalents7,600,5988,912,517
Short-term investments43,08544,422
Accounts receivable, net of allowance for credit losses of $66,775 in 2024 and 2023207,681260,399
Inventories1,193,9521,616,356
Prepaids and other current assets1,018,686498,033
Total current assets10,064,00211,331,727
Non-Current
Property, equipment and ROU assets, net1,370,969723,426
Intangible assets, net1,823,7451,946,279
Other assets100,000104,908
Total Assets13,358,71614,106,340
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current
Accounts payable and accrued liabilities1,183,2851,608,735
Current portion of lease obligations345,545375,713
Deferred rent-16,171
Total current liabilities1,528,8302,000,619
Non-current
Lease obligations, net of current portion725,23615,994
Total Liabilities2,254,0662,016,613
Commitments and Contingencies (Note 11)
Shareholders’ Equity
Common shares, no par value, unlimited authorized shares:
6,344,970 (June 30, 2023 - 3,328,191) issued and outstanding80,606,86377,620,252
Additional paid-in capital37,507,30635,741,115
Accumulated deficit(107,138,088)(101,400,209)
Accumulated other comprehensive income128,569128,569
Total Shareholders’ Equity11,104,65012,089,727
Total Liabilities and Shareholders’ Equity13,358,71614,106,340
Related Party Transactions (Note 12)
Subsequent Events (Note 13)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.